Skip to content


Oricula Therapeutics

Health & Medicine



Oricula Therapeutics is a start-up biotechnology company with a mission to develop medicines that protect hearing and balance from the effects of ototoxic drugs and aging. They have developed the first medication to prevent hearing loss in patients undergoing treatment for serious infections with aminoglycoside antibiotics.

Team Members

Malcolm Gleser,


Edwin Rubel

Co-founder, Virginia Merrill Bloedel Professor of Hearing Sciences, University of Washington

David Raible

Co-founder, Professor of Biological Structure, University of Washington

Henry Ou

Associate Professor of Pediatric Otolaryngology at University of Washington and Seattle Children’s Hospital

Julian Simon

Fred Hutchinson Cancer Research Center

Vince Groppi

University of Michigan

Graham Johnson

Marc Bailie

Michigan State University

Judd Walson

Associate Professor of Global Health, Medicine, Pediatrics, and Epidemiology, University of Washington